Pustular psoriasis is an uncommon but painful and often
debilitating form of psoriasis. We are pleased to be involved with a new
clinical trial study specifically for palmo-plantar pustulosis (pustular psoriasis of the palms of the hands and soles of the feet, otherwise known as 'PPP').
Recent research has shown that PPP may be caused by an abnormal
pathway in the body's immune system, involving a protein called interleukin-1 (IL-1). The medication being tested - anakinra - specifically
blocks this IL-1 pathway, and this clinical trial sets out to test if it therefore improves PPP.
As well as testing anakinra
as a potential new treatment for PPP, this trial also hopes to collect information
from participants that will help to explain why and how people get PPP.
APRICOT collaborators, including the Psoriasis Association, are based around the country,
have been involved in the project from the beginning, and will also be instrumental
in influencing the direction of the trial as part of the trial management
group. This clinical trial is lead by Professor Catherine Smith at St John's Institute of Dermatology, and has been funded by the Efficacy and Mechanism Evaluation (EME) Programme, a Medical Research Council and National Institute for Health Research partnership.
The APRICOT study has recently passed its 'half way recruitment target', however 32 new participants are still required to start as soon as possible. APRICOT is currently open at centres in Bradford, Bristol, Cambridge, Cardiff, Derby, Dudley, Dundee, Harlow, Lancaster, Liverpool, London, Newcastle, Norwich, Poole, and Salford. New centres in Chelmsford, Exeter, Fife, Glasgow, Nottingham and Sheffield are also due to open very soon.
For more information on APRICOT, including how to take part in the clinical trial, please visit the website.